Axogen (AXGN) Asset Writedowns and Impairment (2016 - 2026)
Axogen's (AXGN) quarterly Asset Writedowns and Impairment came in at -$120000.0 in Q1 2026, down 164.17% year-on-year from $187000.0 in Q1 2025, and up 59.18% quarter-over-quarter from -$294000.0 in Q4 2025.
Axogen (AXGN) Asset Writedowns and Impairment (2016 - 2026) Analysis & Trends
Axogen's Asset Writedowns and Impairment history runs 11 years deep, the most recent figure standing at -$120000.0 for Q1 2026.
- On a quarterly basis, Asset Writedowns and Impairment fell 164.17% year-over-year to -$120000.0 in Q1 2026; TTM through Mar 2026 was -$243000.0, a 141.75% decrease from a year earlier, with the FY2025 full-year figure at $64000.0, down 90.15% from the prior year.
- Asset Writedowns and Impairment rose to -$120000.0 in Q1 2026 per AXGN's latest filing, from -$294000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $789000.0 in Q3 2023 and bottomed at -$294000.0 in Q4 2025.
- The 5-year median for Asset Writedowns and Impairment is $199000.0 (2025), against an average of $195529.4.
- Across the five-year window, Asset Writedowns and Impairment soared 1865.38% in 2022 and slumped 739.13% in 2025, its largest moves.
- Year by year, Asset Writedowns and Impairment stood at $46000.0 in 2022, then jumped by 576.09% to $311000.0 in 2023, then sank by 85.21% to $46000.0 in 2024, then slumped by 739.13% to -$294000.0 in 2025, then surged by 59.18% to -$120000.0 in 2026.
- Per Business Quant, the three latest AXGN Asset Writedowns and Impairment figures stand at -$120000.0 (Q1 2026), -$294000.0 (Q4 2025), and -$28000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.73 Bn | 176.43 Bn | 6.27 Bn |
| 2 | Stryker | 129.05 Bn | 126.17 Bn | 3.81 Bn |
| 3 | Medtronic | 108.52 Bn | 99.30 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.63 Bn | 67.18 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.43 Bn | 44.76 Bn | 1.29 Bn |
| 6 | Dexcom | 28.36 Bn | 27.24 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.14 Bn | 25.85 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.89 Bn | 26.32 Bn | - |
| 9 | Koninklijke Philips | 24.25 Bn | 21.12 Bn | 2.07 Bn |
| 10 | Axogen | 2.11 Bn | 2.01 Bn | 46.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -120,000.00 |
| Mar 31, 2026 | -120,000.00 |
| Dec 31, 2025 | -294,000.00 |
| Dec 31, 2025 | -294,000.00 |
| Sep 30, 2025 | -28,000.00 |
| Sep 30, 2025 | -28,000.00 |
| Jun 30, 2025 | 199,000.00 |
| Jun 30, 2025 | 199,000.00 |
| Mar 31, 2025 | 187,000.00 |
| Mar 31, 2025 | 187,000.00 |
| Dec 31, 2024 | 46,000.00 |
| Dec 31, 2024 | 46,000.00 |
| Sep 30, 2024 | 76,000.00 |
| Sep 30, 2024 | 76,000.00 |
| Jun 30, 2024 | 273,000.00 |
| Jun 30, 2024 | 273,000.00 |
| Mar 31, 2024 | 255,000.00 |
| Mar 31, 2024 | 255,000.00 |
| Dec 31, 2023 | 311,000.00 |
| Dec 31, 2023 | 311,000.00 |